Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it

Page 5 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.

• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted
• Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)TerminatedNCT02500901Phase 1Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerCompletedNCT02476968Phase 4Results posted
• Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02470585Phase 3Results posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02412371Phase 1/2Results posted
• Fermented Wheat Germ Extract in Women With Ovarian CancerTerminatedNCT02411565Early Phase 1Results posted
• Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid TumorsCompletedNCT02401347Phase 2Results posted
• A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensCompletedNCT02354586Phase 2Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor TreatmentTerminatedNCT02326844Phase 2Results posted
• Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal CancerCompletedNCT02305758Phase 2Results posted
• Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung CancerCompletedNCT02289690Phase 1/2Results posted
• Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast CancerCompletedNCT02282345Phase 2Results posted
• Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum TreatmentsCompletedNCT02282020Phase 3Results posted
• Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former SmokersCompletedNCT02264990Phase 3Results posted
• Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyCompletedNCT02184195Phase 3Results posted
• A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast CancerCompletedNCT02163694Phase 3Results posted
• Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast CancerCompletedNCT02158507Not applicableResults posted
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02152982Phase 2/3Results posted
• Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)CompletedNCT02137772Phase 3Results posted
• Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent MalignanciesCompletedNCT02116777Phase 1/2Results posted
• To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid CancerCompletedNCT02093351Phase 1Results posted
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)TerminatedNCT02034916Phase 2Results posted
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerActive, not recruitingNCT02032823Phase 3Results posted
• Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.CompletedNCT02000622Phase 3Results posted
• Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsCompletedNCT01989546Phase 1/2Results posted
• Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.CompletedNCT01972217Phase 2Results posted
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedNCT01968213Phase 3Results posted
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)CompletedNCT01945775Phase 3Results posted
• Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.CompletedNCT01924533Phase 3Results posted
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsTerminatedNCT01905592Phase 3Results posted
• A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedNCT01891344Phase 2Results posted
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyActive, not recruitingNCT01874353Phase 3Results posted
• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedNCT01847274Phase 3Results posted
• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Active, not recruitingNCT01844986Phase 3Results posted
• MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsCompletedNCT01827384Phase 2Results posted
• Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerCompletedNCT01818063Phase 2Results posted
• Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid MalignanciesCompletedNCT01813474Phase 1Results posted
• Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking HistoryCompletedNCT01758731Phase 1Results posted
• Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck CancerCompletedNCT01711541Phase 1/2Results posted
• Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung CancerCompletedNCT01657799Phase 2Results posted
• Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT01642251Phase 1/2Results posted
• Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerActive, not recruitingNCT01638546Phase 2Results posted
• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT01585805Phase 2Results posted
• Olaparib in Adults With Recurrent/Metastatic Ewing's SarcomaCompletedNCT01583543Phase 2Results posted
• Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01576172Phase 2Results posted
• Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01540565Phase 2Results posted
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasCompletedNCT01514201Phase 1/2Results posted
• Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib AloneCompletedNCT01513174Phase 1/2Results posted
• Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast CancerCompletedNCT01506609Phase 2Results posted
• ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic CancerCompletedNCT01489865Phase 1/2Results posted
• A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)CompletedNCT01482715Phase 1/2Results posted
• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT01386385Phase 1/2Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid TumorsTerminatedNCT01311713Phase 1/2Results posted
• Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
• Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic CancerCompletedNCT01296763Phase 1Results posted
• Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsCompletedNCT01286987Phase 1Results posted
• Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT01266447Phase 2Results posted
• ABT-888 and Temozolomide for Liver CancerTerminatedNCT01205828Phase 2Results posted
• Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast CancerCompletedNCT01149083Phase 2Results posted
• Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid TumorsTerminatedNCT01127178Phase 1Results posted
• Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerActive, not recruitingNCT01081951Phase 2Results posted
• Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation PatsCompletedNCT01078662Phase 2Results posted
• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsCompletedNCT01074970Phase 2Results posted
• Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted PatientsCompletedNCT01063829Phase 2Results posted
• Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer PatientsCompletedNCT01063517Phase 2Results posted
• A Study of ABT-888 in Combination With Temozolomide for Colorectal CancerCompletedNCT01051596Phase 2Results posted
• Veliparib and Temozolomide in Treating Patients With Recurrent GlioblastomaCompletedNCT01026493Phase 1/2Results posted
• Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerActive, not recruitingNCT01012817Phase 1/2Results posted
• ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast CancerCompletedNCT01009788Phase 2Results posted
• Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) StatusCompletedNCT00912743Phase 2Results posted
• A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic MelanomaCompletedNCT00804908Phase 2Results posted
• Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerCompletedNCT00753545Phase 2Results posted
• Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast CancerCompletedNCT00679783Phase 2Results posted
• Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian CancerCompletedNCT00628251Phase 2Results posted
• Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian CancerCompletedNCT00494442Phase 2Results posted
• Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast CancerCompletedNCT00494234Phase 2Results posted
• A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian CancerWithdrawnNCT07060365Phase 1/2
• A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting StateCompletedNCT07030439Phase 1
• An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting ConditionCompletedNCT07019194Phase 1
• FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06909825Phase 2
• Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of SaruparibActive, not recruitingNCT06899061Phase 1
• Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)WithdrawnNCT06719973Phase 1
• PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerActive, not recruitingNCT06612814Phase 3
• Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate CancerWithdrawnNCT06527690Phase 2
• SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARCStatus unknownNCT06516445Phase 2
• CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCTActive, not recruitingNCT06449586Phase 3
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2
• A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated GlioblastomaActive, not recruitingNCT06388733Phase 3
• Study of ACE-86225106 to Treat Patients With Advanced Solid TumorsActive, not recruitingNCT06380660Phase 1/2
• Niraparib and Dostarlimab for Patients with MMR-D/MSI-H Colorectal CancersWithdrawnNCT06365970Phase 2
• High-Risk Metachronous Oligometastatic Prostate Cancer TrialActive, not recruitingNCT06212583Phase 2
• Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated TumorsActive, not recruitingNCT06177171Phase 1
• ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid TumorsWithdrawnNCT06161493Phase 1
• Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung CancersTerminatedNCT06130254Phase 1
• First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive PatientsActive, not recruitingNCT06121401Phase 4
• Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination DeficiencyWithdrawnNCT06120972Phase 2

← Poly(ADP-ribose) Polymerase Inhibitors overview